Recent clinical studies, including the Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndrome and Evolocumab in Acute Coronary Syndrome trials, have validated the beneficial impact of pre-percutaneous coronary intervention (PCI) use of PCSK9 inhibitors in patients with ASCVD, demonstrating an improved patient prognosis, reduced incidence of major adverse cardiovascular events, and decreased overall mortality rate. This evidence concerns the gene PCSK9 and atherosclerosis.